Menin is required in cranial neural crest for palatogenesis and perinatal viability.

Menin is required in cranial neural crest for palatogenesis and perinatal viability. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Menin is required in cranial neural crest for palatogenesis and perinatal viability. Abstract Text:

Kurt A Engleka,Meilin Wu,Maozhen Zhang,Nicole B Antonucci,Jonathan A Epstein,Kurt A Engleka,Meilin Wu,Maozhen Zhang,Nicole B Antonucci,Jonathan A Epstein,

Menin is a nuclear protein encoded by a tumor suppressor gene that is mutated in humans with multiple endocrine neoplasia type 1 (MEN1). Menin functions as a component of a histone methyltransferase complex that regulates expression of target genes including the cell cycle inhibitor p27(kip1). Here, we show that menin plays a previously unappreciated and critical role in cranial neural crest. Tissue-specific inactivation of menin in Pax3- or Wnt1-expressing neural crest cells leads to perinatal death, cleft palate and other cranial bone defects, which are associated with a decrease in p27(kip1) expression. Deletion of menin in Pax3-expressing somite precursors also produces patterning defects of rib formation. Thus, menin functions in vivo during osteogenesis and is required for palatogenesis, skeletal rib formation and perinatal viability.

Menin is required in cranial neural crest for palatogenesis and perinatal viability. Publishing Authors By Initials

KA Engleka,M Wu,M Zhang,NB Antonucci,JA Epstein,KA Engleka,M Wu,M Zhang,NB Antonucci,JA Epstein,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Menin is required in cranial neural crest for palatogenesis and perinatal viability. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Developmental biology

VOLUME: 311

Page Numbers: 524-37

Journal Abbreviation:

ISSN: 1095-564X

DAY: 7

MONTH: 09

YEAR: 2007

Menin is required in cranial neural crest for palatogenesis and perinatal viability. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372762

Menin is required in cranial neural crest for palatogenesis and perinatal viability. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Menin is required in cranial neural crest for palatogenesis and perinatal viability. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Menin is required in cranial neural crest for palatogenesis and perinatal viability.

AFFILIATION: Department of Cell and Developmental Biology and the Cardiovascular Institute, University of Pennsylvania, 1154 BRB II, 421 Curie Blvd, Philadelphia, PA 19104, USA.

Country: United States

AGENCY: United States NHLBI

GRANT: R01 HL 61475

ACRONYM: HL

MEDLINETA: Dev Biol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Menin is required in cranial neural crest for palatogenesis and perinatal viability Related Publications

• A pharmacy benefit manager perspective.
• Analgesic and Antiinflammatory Activity of Antibodies to Histamine under Experimental Conditions.
• Antibodies to delta sleep-inducing Peptide in ultralow doses: study of the effect by enzyme immunoassay.
• Antiulcer Activity of Ultralow Doses of Antibodies to Histamine under Experimental Conditions.
• Changes in Immunological Parameters in Patients with Opium Abuse Receiving ANAR Therapy.
• Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum.
• Co-twin control designs for testing behavioral economic theories of child nutrition: methodological note.
• Coexistence, competition and hypercyclic interaction in some systems of biological interest.
• Effect of Potentiated Antibodies to Cyclophosphamide on the Development of Tumors and Effectiveness of Cytostatic Therapy under Experimental Conditions.
• Effect of Potentiated Solutions on Mercury(II) Signal in Inversion Voltammetry.
• Effect of Preparations from Potentiated Ethanol on the Content of Biogenic Monoamines and Metabolism of Ethanol in Tissues of Rats during Alcoholization.
• Effect of allotransplantation of embryonic brain tissues and administration of potentiated antibodies to bombesin on hemodynamics in rats with emotional hypertension.
• Effect of antibodies to morphine in ultralow doses on induction of long-term potentiation in hippocampal slices from rats with chronic morphine dependence.
• Effect of potentiated antibodies to morphine on behavioral reactions in rats with morphine dependence.
• Effects of Potentiated Antibodies Against Brain-Specific S100 Protein on Biogenic Amine Content and Lipid Peroxidation in Rats under Conditions of Alcoholization.
• Effects of ultralow doses of antibodies to prostate-specific antigen on morphological and functional state of rat prostate.
• Efficiency of ultralow doses of antibodies to s100 protein and delta sleep-inducing Peptide in rats with anxious depression.
• Impaza and sildenafil: comparison of clinical effectiveness in patients with erectile dysfunction.
• Membranotropic effects of antibodies to s100 protein in ultralow doses.
• Metallothionein and catalase sensitize to diabetes in nonobese diabetic mice: reactive oxygen species may have a protective role in pancreatic beta-cells.
• Potentiated Antibodies to Tumor Necrosis Factor-alpha in the Therapy of Patients with Rheumatoid Arthritis.
• Potentiated antibodies against morphine: effects on biogenic amines and lipid peroxidation in chronically morphinized rats.
• Potentiated cyclophosphane: experimental study of the effect on tumor development and efficiency of cytostatic therapy.
• Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome.
• Regulatory activity of ultralow doses.
• Relationship between sex of parent and child on weight loss and maintenance in a family-based obesity treatment program.
• Reperfused myocardial infarction in mice: 3D mapping of late gadolinium enhancement and strain.
• The challenge of Down syndrome.
• Ultralow Doses of Anti-Idiotypic Antibodies to Human gamma-Interferon: Immunotropic Properties.
• Use of potentiated preparations to relieve alcohol and opium withdrawal syndromes.